Defactinib

• Product Name Alternative:

  VS-6063; PF-04554878

• UNSPSC Description:

  Defactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.

• Target Antigen:

  FAK

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Defactinib.html

• Purity:

  99.87

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(NC)C1=CC=C(NC2=NC=C(C(F)(F)F)C(NCC3=NC=CN=C3N(C)S(=O)(C)=O)=N2)C=C1

• Molecular Weight:

  510.49

• References & Citations:

  [1]Kang Y, et al. Role of focal adhesion kinase in regulating YB-1-mediated resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.ACS Appl Mater Interfaces. 2024 Oct 1.|ACS Nano. 2023 Jan 4.|Biochem Biophys Res Commun.. 2024 Sep 17.|bioRxiv. 2024 November 26.|Bone. 2021 Oct 12;116231.|Cancer Commun (Lond). 2024 Jul 28.|Cell Death Dis. 2021 Sep 23;12(10):868.|Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696.|Clin Breast Cancer. 2024 Jan 26.|Exp Cell Res. 12 October 2021, 112868.|Exp Ther Med. 2020 Aug;20(2):1405-1414.|Front Oncol. 2022 Apr 28;12:851065.|Heliyon.2024 Aug 6;10(16):e35727.|J Exp Clin Cancer Res. 2018 Jul 28;37(1):175.|J Exp Clin Cancer Res. 2022 Sep 16;41(1):275.|J Int Med Res. 2018 Apr;46(4):1311-1325. |J Orthop Transl. 2020 May 19;24:12-22.|J Transl Med. 2023 Sep 19;21(1):640.|Mol Carcinog. 2023 Oct 3.|Nat Commun. 2023 Apr 29;14(1):2478.|Nat Commun. 2019 Aug 16;10(1):3708. |Oncogene. 2023 Feb 23.|Oncogene. 2024 Aug 22.|Oncol Res. 2024 Mar 20;32(4):679-690.|Phytomedicine. 21 July 2022, 154349.|Placenta. 2024 Aug 21:156:30-37.|Research Square Print. September 13th, 2022.|Sci Data. 2024 Sep 19.|Sci Rep. 2019 May 20;9(1):7617.|Science. 2017 Dec 1;358(6367):eaan4368.|University of Zürich. Department of Dermatology. 2021 Dec.|Bioact Mater. 1 July 2021.|Bioact Mater. 2021 Jun 1.|bioRxiv. 2023 Mar 2.|Mater Sci Eng C Mater Biol Appl. 2020 Jan;106:110221.|Mol Metab. 2023 Feb 24;101698.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2021 Aug.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 3

• CAS Number:

  1073154-85-4